 hold pt macro pressur revenu preview settlement
put guidanc risk lower pt maintain hold analyst nehal chokshi full summari
envis solar intern inc evsi buy pt continu expect revenu tripl new
trovagen inc trov buy pt onvansertib data prostat cancer- continu earli signal efficaci
corpor event call maxim salesperson inform
corp ndr nyc ceo sherif foda thu-fri sep
northwest natur cover sullivan ndr nyc cfo frank burkhartsmey wed sep
corpor cover ndr boston ceo john miller svp robert verostek
coffe hold co inc jva cover ndr boston ceo andi gordon wed sep
california restaur tour habt host mon-tu
splunk inc cover chokshi group luncheon san francisco svp cfo jason child wed
inc cover klee ndr boston presid ceo michael prior cfo justin
inc cover klee ndr nyc ceo presid steve pickett cfo ahlstrom thu
inc cover klee ndr boston ceo presid steve picket cfo ahlstrom fri
inc cover klee ndr boston cfo toni pritchett vice-president financ david wood
inc cover klee ndr nyc cfo paul martin tue sep
chicken soup soul entertain inc csse cover klee ndr nyc chairman ceo rouhana
chief staff amanda romaniello fri sep
macro pressur revenu preview settlement
put guidanc risk lower pt maintain
juli quarter gross profit y/i modest posit despit overal
revenu y/i consist august industri note take-
oct ep guidanc in-lin full-year guidanc rais consist jul beat
lower revenu estim modestli rais
price target reduc take account
settlement modestli lower estim lower end
juli quarter gross profit y/i modest posit despit overal
revenu y/i consist august industri note take-down
last night report jul revenu y/i
q/q slightli consensu estim exclud
fx headwind on-going transit tier hyper-scal custom overal
revenu y/i q/q gross margin
y/i impress light weak macro environ gm expans
extend seven sequenti quarter begin jan driven
quarter commod price tailwind favor portfolio mix shift non-
oper profit y/i q/q beat consensu
estim non-gaap ep y/i q/q
guidanc rang outperform rel consensu well
estim adjust commod price tailwind expect
wane go estim jul gross profit estim flat slightli
y/i basi stori sustain gross profit growth remain
elus view
oct guidanc in-lin full-year guidanc rais consist jul beat
modestli rais estim manag provid ep guidanc
consensu maxim rais ep guidanc
rang consist jul beat revis ep rang
midpoint prior guidanc
rais ep estim leav ep estim
rel unchang
price target reduc take account
settlement modestli lower estim lower end
guidanc ep midpoint guidanc rais
mirror juli out-performance midpoint guidanc
maintain addit manag re-affirmed guidanc
howev given risk unchang guidanc may reflect
pull-in work capit benefit off-set
nr settlement expect made oct reduc
estim price target reduc
base multipl reduc due lower growth
project estim less non-accret
acquisit plu oper net cash maintain hold rate
click full note
continu expect revenu tripl new
exist custom maintain buy price target
maintain forecast evsi tripl revenu base multipl order
opportun new exist custom
instanc one potenti order citi san diego may
request propos mobil solar panel electr vehicl charg
forecast evsi increas revenu million million
without use debt addit equiti
san diego identifi city-own properti potenti site electr
believ evsi submit bid order sinc evsi previous
announc order counti san diego also base
expect san diego final contract associ may
request propos rfp end year
citi request electr vehicl charg propos view similar
may rfp citi san diego believ evsi order
opportun citi continu decreas custom concentr
instanc evsi custom concentr decreas one custom
account revenu prior quarter separ
believ mani state local govern increas budget year
nation associ state budget offic nasbo report last month
state increas revenu fiscal year mostli end june exampl
california revenu exceed state forecast billion indiana
end fiscal surplu spend one-tim capit project separ
evsi announc last week work nine top municip fleet
evsi million cash fund growth debt expect evsi
tripl revenu current fund evsi use proce april
equiti offer pay compani debt reduc liabil increas
inventori rais million net proce april equiti offer
evsi reduc liabil million end million cash debt
million account payabl million prior quarter evsi
also increas inventori million million believ
evsi convert million inventori account payabl cash base
previou receiv writedown histor declin inventori revenu
maintain buy rate price target current ev/revenu multipl
revenu forecast million base price target ev/
revenu multipl revenu estim million although
revenu forecast chang previou ev/revenu multipl target
base updat balanc sheet forecast includ lower inventori balanc
versu cash evsi peer group averag forward ev/revenu multipl
includ multipl blink charg blnk rate off-set lower multipl
compani make electr vehicl and/or sell off-grid electr product
click full note
onvansertib data prostat cancer- continu earli
signal efficaci
trovagen present addit data studi onvansertib
combin zytiga/prednison patient metastat castration-
resist prostat cancer mcrpc asia-pacif prostat cancer
confer melbourn australia
present includ data initi dose schedul
arm dose-intensifi arm focu
patient patient variant develop resist zytiga
androgen receptor inhibitor rapidli thu far
variant patient experienc initi reduct stabil includ
two primari efficaci endpoint one start week
overal posit signal efficaci onvansertib build upon prior
earli data april see note link difficult treat popul
phase studi prostat cancer open-label multicent studi
evalu onvansertib combin zytiga abirateron /prednison patient
metastat castration-resist prostat mcrpc trial enrol mcrpc
patient show earli sign diseas progress demonstr
two rise valu abiraterone/prednison evalu proport
patient achiev diseas control week combin treatment studi
arm arm dose everi week arm dose everi week
patient dose thu far arm arm primari
endpoint achiev patient arm arm importantli
arm subject demonstr initi efficaci signal suggest week
dose higher drug exposur may maxim respons treatment anoth key
point patient aggress sub-typ display encourag
result thu far patient complet dose variant
current dose demonstr initi stabilization/reduct patient
achiev primari endpoint
mcrpc metastat castrat resist prostat cancer aggress
incur lethal cancer nearli patient prostat cancer eventu
progress castrat resist newli diagnos castration-resist prostat
cancer metastas current ar inhibitor zytiga xtandi first
line treatment mcrpc howev resist typic develop within month
treatment left iv chemotherapi docetaxel cabazitaxel
produc modest surviv improv month docetaxel
ar inhibitor paper link respons rate reduc vs
psa-pf lower month vs month overal
surviv also reduc month vs month
click full note
maxim analyst coverag univers
sector coverag
care well
industri util
